Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

May 20, 2026

Study Completion Date

November 20, 2026

Conditions

Liver Cancer

Interventions

BIOLOGICAL

Oral enterobacterium capsules

Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.

DRUG

Lenvatinib + PD-1 monoclonal antibody

"Lenvatinib 8mg (≤60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day.~PD-1 monoclonal antibody 200mg i.v. once every 3 weeks."

BIOLOGICAL

Oral enterobacterium capsules placebo

Enterobacterium capsules placebo (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.

All Listed Sponsors

collaborator

Nanjing Xiershou Biotechnology Co., Ltd

UNKNOWN

lead

Xu Yong, MD

OTHER

NCT06563934 - Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs) | Biotech Hunter | Biotech Hunter